Christopher S. Henney's most recent trade in Cyclacel Pharmaceuticals Inc was a trade of 42,438 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 30, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 42,438 | 42,438 | - | - | Stock Option (right to buy) | |
| Cyclacel Pharmaceuticals Inc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 21,219 | 39,415 (0%) | 0% | 0 | Common Stock | |
| Cyclacel Pharmaceuticals Inc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 31,645 | 31,645 | - | - | Stock Option (right to buy) | |
| Cyclacel Pharmaceuticals Inc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 15,822 | 18,196 (0%) | 0% | 0 | Common Stock | |
| Prothena Corporation plc | Christopher S. Henney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2021 | 11,108 | 0 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.33 per share. | 14 Jul 2021 | 11,108 | 11,108 (0%) | 0% | 11.3 | 125,854 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 55.31 per share. | 14 Jul 2021 | 9,108 | 2,000 (0%) | 0% | 55.3 | 503,757 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 56.13 per share. | 14 Jul 2021 | 2,000 | 0 (0%) | 0% | 56.1 | 112,263 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.23 per share. | 12 Jul 2021 | 17,500 | 17,500 (0%) | 0% | 9.2 | 161,525 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.33 per share. | 12 Jul 2021 | 6,392 | 6,392 (0%) | 0% | 11.3 | 72,421 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 6,392 | 11,108 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 53.84 per share. | 12 Jul 2021 | 6,228 | 11,272 (0%) | 0% | 53.8 | 335,334 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 54.55 per share. | 12 Jul 2021 | 5,886 | 5,386 (0%) | 0% | 54.6 | 321,105 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 55.95 per share. | 12 Jul 2021 | 2,475 | 2,911 (0%) | 0% | 55.9 | 138,476 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 55.26 per share. | 12 Jul 2021 | 2,315 | 4,077 (0%) | 0% | 55.3 | 127,920 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 56.56 per share. | 12 Jul 2021 | 2,100 | 1,977 (0%) | 0% | 56.6 | 118,767 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 56.88 per share. | 12 Jul 2021 | 1,634 | 1,277 (0%) | 0% | 56.9 | 92,934 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 58.66 per share. | 12 Jul 2021 | 800 | 477 (0%) | 0% | 58.7 | 46,924 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 57.85 per share. | 12 Jul 2021 | 700 | 1,277 (0%) | 0% | 57.9 | 40,498 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 59.24 per share. | 12 Jul 2021 | 600 | 177 (0%) | 0% | 59.2 | 35,547 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 58.21 per share. | 12 Jul 2021 | 500 | 777 (0%) | 0% | 58.2 | 29,106 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 59.45 per share. | 12 Jul 2021 | 300 | 177 (0%) | 0% | 59.4 | 17,834 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 61.25 per share. | 12 Jul 2021 | 177 | 0 (0%) | 0% | 61.2 | 10,841 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 61.25 per share. | 12 Jul 2021 | 177 | 0 (0%) | 0% | 61.2 | 10,841 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2021 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.43 per share. | 25 Jun 2021 | 12,000 | 12,000 (0%) | 0% | 16.4 | 197,160 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 47.57 per share. | 25 Jun 2021 | 10,264 | 1,736 (0%) | 0% | 47.6 | 488,223 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale of securities on an exchange or to another person at price $ 48.73 per share. | 25 Jun 2021 | 1,736 | 0 (0%) | 0% | 48.7 | 84,597 | Ordinary Shares, par value $0.01 per share |
| Cyclacel Pharmaceuticals Inc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,748 | 4,748 | - | - | Stock Option (right to buy) | |
| Cyclacel Pharmaceuticals Inc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 2,374 | 2,374 (0%) | 0% | 0 | Common Stock | |
| Prothena Corporation plc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 15,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 15,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 12,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 9,803 | 9,803 | - | - | Employee Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 8,426 | 8,426 | - | - | Employee Stock Option (Right to Buy) | |
| Prothena Corporation plc | Christopher S. Henney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 6,315 | 6,315 | - | - | Employee Stock Option (Right to Buy) |